- STAT+: Biogen Alzheimer’s drug slowed decline at rates on par with approved therapies, study showsAn experimental Alzheimer's drug from Biogen, one with a novel approach, slowed decline at comparable rates as approved drugs in a mid-stage study.STAT · 14d ago↗ source
- Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugsThe study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.BioPharma Dive · 14d ago↗ source
- FDA authorized Zyn nicotine pouches without knowing what they were made of, says former agency scientistA former FDA toxicologist has accused the agency of authorizing Zyn nicotine pouches without fully reviewing their safety